Piramal Life Sciences, Mumbai based drug developer on Wednesday said it had received regulatory approval by Drug Controller General of India to conduct two Phase I/II combination studies for its cancer molecule P276 which would help it develop drugs against pancreatic, head and neck cancer.
The objective of both studies is to identify the right doses of P276 to be used in combination with chemotherapeutic drugs and to evaluate the benefit of the same in pancreatic and head and neck cancer patients, the company said in a note to the stock exchanges.
The stock of the company was up by 4.9 per cent to Rs51.50 a share on Bombay Stock Exchange at 12.00 pm. The company has the upper circuit limit of 5 per cent daily increase on the exchange.
